1. Home
  2. MNTK vs AGEN Comparison

MNTK vs AGEN Comparison

Compare MNTK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montauk Renewables Inc.

MNTK

Montauk Renewables Inc.

SELL

Current Price

$2.40

Market Cap

267.6M

Sector

Utilities

ML Signal

SELL

Logo Agenus Inc.

AGEN

Agenus Inc.

SELL

Current Price

$7.43

Market Cap

274.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MNTK
AGEN
Founded
1980
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.6M
274.8M
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
MNTK
AGEN
Price
$2.40
$7.43
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$1.70
★ $26.33
AVG Volume (30 Days)
860.9K
★ 1.1M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
★ $176,382,000.00
$42,877,086.00
Revenue This Year
$20.76
$9.64
Revenue Next Year
$16.15
N/A
P/E Ratio
$146.00
★ $8.03
Revenue Growth
0.37
★ 89.95
52 Week Low
$1.07
$2.71
52 Week High
$3.28
$10.19

Technical Indicators

Market Signals
Indicator
MNTK
AGEN
Relative Strength Index (RSI) 47.35 43.84
Support Level $1.40 $6.51
Resistance Level $2.73 $8.64
Average True Range (ATR) 0.27 0.61
MACD -0.05 -0.20
Stochastic Oscillator 15.69 5.59

Price Performance

Historical Comparison
MNTK
AGEN

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: